Search results
Results from the WOW.Com Content Network
FTC scrutiny. The FTC's track record on pharma deals isn't great. It previously tried, unsuccessfully, to block Amgen’s $28 billion acquisition of Horizon Therapeutics.It asked for more details ...
The meeting is expected to cover topics including Medicare drug price negotiations, the role of pharmacy benefit managers, and tariffs on pharmaceutical products, according to an industry source ...
The data surveyed by Reuters came from pharmaceutical regulators in Australia, Brazil, New Zealand and the United States; information from a commercial customs data provider for Kenya, Uzbekistan ...
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study. About DelveInsight. DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
It provides daily news and analysis on the biotechnology and pharmaceutical industry including areas such as policy & regulation, business news, research & development, generics, drug delivery, and clinical trials. In 2022, Informa sold its Pharma Intelligence division, including Scrip, to Warburg Pincus. [4] The business was renamed Citeline.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Welcome to your ultimate source for all things money-related. Join us as we cover personal finance, investing, business news, and global economic trends. Learn how to budget, save money on your TV watching, or find apps to help with managing your finances and growing your wealth.
On average, it takes over a decade and $2.3 billion for a pharmaceutical company to develop a new medication, an expensive slog that few companies want to risk tinkering with. Introducing a new ...